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ABSTRACT
We hypothesized that aberrations activating epidermal growth factor receptor 
(EGFR) via dimerization would be more sensitive to anti-dimerization agents (e.g., 
cetuximab). EGFR exon 19 abnormalities (L747_A750del; deletes amino acids LREA) 
respond to reversible EGFR kinase inhibitors (TKIs).  Exon 20 in-frame insertions 
and/or duplications (codons 767 to 774) and T790M mutations are clinically resistant 
to reversible/some irreversible TKIs.  Their impact on protein function/therapeutic 
actionability are not fully elucidated. 
In our study, the index patient with non-small cell lung cancer (NSCLC) 
harbored EGFR D770_P772del_insKG (exon 20).  A twenty patient trial (NSCLC 
cohort) (cetuximab-based regimen) included two participants with EGFR TKI-
resistant mutations ((i) exon 20 D770>GY; and (ii) exon 19 LREA plus exon 20 
T790M mutations). Structural modeling predicted that EGFR exon 20 anomalies 
(D770_P772del_insKG and D770>GY), but not T790M mutations, stabilize the active 
dimer configuration by increasing the interaction between the kinase domains, hence 
sensitizing to an agent preventing dimerization. Consistent with predictions, the two 
patients harboring D770_P772del_insKG and D770>GY, respectively, responded to 
an EGFR antibody (cetuximab)-based regimen; the T790M-bearing patient showed no 
response to cetuximab combined with erlotinib. In silico modeling merits investigation 
of its ability to optimize therapeutic selection based on  structural/functional 
implications of different aberrations within the same gene.
INTRODUCTION 
Patients suffering from lung cancers that harbor 
EGFR-sensitive mutations are responsive to reversible 
EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib 
[1, 2]. In about 60% of cases initially sensitive to reversible 
EGFR inhibitors, the T790M mutation emerges; these are 
generally resistant to both reversible and some irreversible 
TKIs (e.g., afatinib) in the clinic [3–6]. In other patients 
(~4 to ~13 percent each), MET and HER2 amplification 
are operative in resistance [7, 8]. A small, but important, 
subgroup of patients carry EGFR exon 20 insertion 
mutations (in-frame insertions and/or duplications of 3 to 
21 base pairs clustered between codons 767 and 774 in 
EGFR exon 20), which are known to be generally resistant 
to both reversible and new irreversible TKIs in the clinic 
[3]. 
The extracellular antibody cetuximab can also target 
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EGFR. It functions by partially blocking the EGFR ligand-
binding domain and sterically hindering exposure of the 
dimerization domain, hence decreasing docking of the 
two monomeric EGFRs to each other and, in this way, 
attenuating dimerization-dependent EGFR activity [9]. 
Antitumor activity of cetuximab is observed in patients 
with EGFR wild-type colorectal and head and neck 
cancers, but not in many other tumor types [10–12]. The 
mechanism of action of wild-type EGFR is primarily 
driven by receptor dimerization followed by kinase 
activation [13]. Shan and colleagues have postulated that 
EGFR L834R exon 21 mutations (also called L858R) 
counteract the intrinsic disorder in the EGFR kinase and, 
therefore, facilitate dimerization, which in turn promotes 
kinase activation [2]. 
To date, the exact mechanisms by which each of 
the EGFR mutations mediates pathway activation and 
carcinogenesis remains incompletely elucidated. Further, 
there are multiple reversible and irreversible EGFR TKI 
inhibitors and antibodies available for clinical use, but 
matching patients with an individual agent occurs largely 
based on empiric data. We therefore modeled the structure 
of EGFR mutants in patients with non-small cell lung 
cancer (NSCLC) and correlated clinical outcomes with 
predicted functional implications. These studies form a 
proof-of-principle demonstration of the ability of in silico 
modeling to be used to choose therapy for individuals, 
and suggest that further investigation in larger cohorts of 
patients is needed. 
RESULTS 
Structural modeling
D770 region (insertion exon 20) mutants
Exon 20 region is the same in the wild type (wt) 
and the modeled exon 19 LREA mutant (Figure 1A), but 
differs from the two modeled exon 20 mutants’ possible 
structures (D770>GY, Figure 1B and D770_P772del_
insKG, Figure 1C). Erlotinib has a similar position inside 
the wt or LREA mutant EGFR tyrosine kinase pocket. It 
is docked in the ATP-binding pocket without constraints 
(Figure 1A). When the mutation D770>GY is introduced, 
it can create significant changes in the conformation of 
the loop (yellow in Figure 1B). Its conformation is quite 
different in comparison with the wt loop (Figure 1A). 
This conformation can be stabilized by a hydrogen bond 
between the residues ASN772 and TYR828, π-cation 
interaction of ARG777 with TRP731, and hydrophobic 
interactions of VAL77 with LEU834 and VAL73, PRO81 
with TYR136. Residue CYS275 located in the “back wall” 
of the ATP-binding pocket plays a role in positioning of 
Figure 1: Interaction between drugs (ball-and-stick 
presentation) and kinase domains of EGFR (brown-
the first domain and violet-the second domain). (A) 
LREA mutant EGFR interacting with erlotinib. CYS775 can 
have a hydrophobic interaction with the drug; the exon 20 
structure of the exon 19 LREA EGFR mutant is similar to that 
found in wt EGFR. The region of the first domain that was not 
changed due to this mutations (ribbon) is in yellow. (B) Model 
of a D770>GY mutant. Absence of the negative ASP770 affects 
electrostatic interaction between the kinase subunits. CYS775 is 
moved by this mutation far from the front atoms of the erlotinib 
causing its unstable positioning in the ATP-binding pocket. The 
region of the first domain that was changed due to the mutations 
(ribbon) is in yellow. (C) Model of D770_P772del_insKG 
mutant. LYS770 introduced by the mutation and absence of 
the ASP770 affect electrostatic interaction between the kinase 
subunits. The region of the first domain that was changed due to 
the mutations (ribbon) is in yellow.
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incoming erlotinib. After a D770>GY mutation, residue 
CYS275 is located significantly farther from the drug’s 
closest heavy atom. The absence of such a wall residue 
makes position of the drug in the pocket less defined 
(not having energy minimum in a proper position) and it 
can be significantly shifted. Such a shift can affect ATP 
competition for the binding site with the drug and activate 
the kinase despite erlotinib. 
In the D770_P772del_insKG mutant, the new 
conformation of the loop (yellow in Figure 1C) is 
stabilized by the set of hydrophobic interactions. 
Specifically, interactions of: VAL769 with PHE855 
and VAL765; VAL773 with ILE852; and CYS774 with 
MET766 and the hydrophobic “stem” of LYS851. The 
resulting loop has CYS775 also located quite far from 
the previous position with consequences similar to those 
described above for the D770>GY mutation. While the 
question of resistance of exon 20 mutants to the reversible 
EGFR inhibitors has been previously discussed [14, 15], 
the other issue as to why these mutations activate EGFR 
has not been well described. One of the explanations can 
be that these mutants can introduce some uncertainty in 
the position of ATP with changes in its phosphorylation 
potential. Another explanation can be related to changes 
in the electrostatic docking profile of the kinase’s active 
dimer. The active configuration of this dimer is very tight 
and practically does not leave possible water enclaves 
(Figure 2). This fact increases the importance of possible 
electrostatic interactions between the domains that have a 
number of complementary positive and negative regions 
(Figure 3A). 
We measured the electrostatic interactions between 
the two kinase domains of the EGFR dimer in active 
configuration and found that both mutations (D770_
P772del_insKG and D770>GY) increase the attractive 
negative energy of inter-protein interaction (Table 1, 
Figure 4). The positive potential of the D770_P772del_
insKG mutation region (outlined by dashed squares in 
Figure 3B) increases versus wild type (Figure 3A) with 
the subsequent increase in electrostatic interactions 
between the kinase domains of EGFR. This effect leads to 
“stabilization” of the dimeric active position. EGFR exists 
in equilibrium between the active and inactive dimers, and 
when it stays longer in the active dimer position, it would 
be more active. 
T790M mutant 
The T790M mutation can result in enhanced 
affinity for ATP, and the subsequent activation is at 
Figure 2: Surface presentation of the active dimer of the 
wt EGFR kinase subunits. Note the close complementary 
interaction of the subunits. 
Figure 3: Electrostatic potentials profile of the kinase 
domains of EGFR dimer. Blue—positive potential (+0.75e), 
red—negative (-0.75e). The mutated regions are outlined by 
the dashed square. The positive potential of the “left” kinase 
domains increases and extends closer to the negative potential 
of the “right” kinase domain. This fact causes increase of the 
attractive electrostatic energy of interaction: (A) WT EGFR; 
(B) D770_P772del_insKG mutant. The significant increase of 
positive electrostatic potential in the area of dimer interface is 
caused by the exon 20 insertion aberrations. 
Table 1:  Electrostatic energy of interaction of the 
intracellular kinase domains in active conformation 
after mutations.
Protein ΔΔE (kJ/mol) 
EGFR WT    0
EGFR T790M    0
EGFR D770_P772del_insKG -93.93±10.5 
EGFR D770>GY -71.88±7.5 
LREAdel exon 19 mutation -60.54±6.3 
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least five fold compared to wild type [16]. In general, 
lung cancers caused by activating EGFR mutations are 
initially responsive to TKIs until second mutations, such 
as T790M, emerge and confer resistance by sterically 
blocking binding of TKIs [4]. Erlotinib docks to the ATP-
binding pocket of EGFR without serious restraints in 
the case of the sensitive exon 19 LREA mutant (Figure 
5A). The T790M mutation brings structural changes to 
the ATP-binding pocket (Figure 5B). Specifically, the 
bulky hydrophobic chain of MET790 that substitutes for 
THR790 (Figure 5B) will prevent the proper positioning 
of erlotinib and other reversible TKIs, introducing 
resistance to them. At the same time, the irreversible 
inhibitor afatinib, despite close resemblance to erlotinib’s 
structure, inhibits the T790M mutant EGFR, at least in 
preclinical models (albeit with only minimal activity in 
the clinic) [17, 18]. Crystal structure of the kinase domain 
of EGFR with afatinib (Figure 5C) shows that it forces 
conformational changes in MET790 side chains [17]. A 
covalent bond between the drug and CYS797 causes this 
effect, making afatinib more stable in the binding position. 
When the side chain of MET790 is in the conformation 
adjusted to afatinib binding, that position would compete 
with ATP and allow afatinib to some extent to serve as a 
drug.
We checked the impact of T790M mutation on 
energy of interactions between the kinase domains of the 
active dimer of EGFR. We used the same method as for 
all abovementioned mutants. We found that there were 
no changes in electrostatic energy of the kinase domain 
interactions and consequently no changes of activity of 
EGFR (and no response to cetuximab) are predicted for 
that mutant (Table 1).
LREA deletion mutant 
The del747–750 mutation in exon 19 activates 
EGFR. This mutation can significantly change the 
conformation of a protein in this region from the initial 
(Figure 6A) to the conformation with increased attractive 
electrostatic energy between the kinase domains of EGFR 
(Figure 6B, Table 1). This change can also prolong the 
“active dimer” configurational state. The effect of the 
LREA mutation on the active dimer stabilization can be 
less than that of the exon 20 aberrations D770_P772del_
insKG and D770>GY because of positioning of the 
residues 747–750 close to the surface of the protein in 
the LREA mutation. The LREA mutation however may 
be sensitive to cetuximab too, albeit less so than the 
exon 20 insertion deletion mutants. Taking into account 
that the LREA mutant is known to be sensitive to the 
reversible TKI inhibitors, it may be that combination 
therapy (including an EGFR TKI inhibitor and EGFR 
antibody) can enhance response. Such a conclusion would, 
however, require a randomized study of an EGFR TKI 
versus an EGFR TKI combined with EGFR antibody, in 
order to be validated in patients. Based on this structural 
and electrostatic profile analysis, it would be predicted 
that when the somatic mutation T790M occurs, the 
Figure 4: Scheme of interactions between the EGFR proteins in the active dimer (brown and violet). Positive–negative 
electrostatic interactions zone (red and blue circles) between the kinase domains of EGFR is caused by the mutations of exons 19 and 20 
presented in the brown boxes. 
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Figure 5: Interactions of erlotinib and afatinib in the ATP-binding pocket of EGFR kinases. (A) Erlotinib in the wt or LREA 
mutant ATP-binding pocket. (B) Erlotinib in the T790M mutant ATP-binding pocket. Methionine 790 can prevent its proper positioning 
in the pocket causing instability and eventual departure because of an unstable position inside the pocket and competition with ATP. (C) 
Afatinib in the T790M mutant ATP-binding pocket. Covalent interaction with CYS797 makes it possible to stabilize the drug in the pocket. 
Table 2:  Characteristics of patients with lung cancer, EGFR mutations and response to cetuximab-based therapy.
Case 
No. Age/Sex/Race Diagnosis
Smoker
Yes/No EGFR Aberrations
Response 
to erlotinib 
alone
Response to 
cetuximab-
based regimen
Comment
1 75/Male/ Caucasian 
Adenocarcinoma 
of the lung 
with pleural 
metastases 
Yes (30 
pack 
year)
exon 20 (D770>GY) Unknown 
Partial response, 
still progression-
free at 42 months 
(Figure 7) 
Received 
cetuximab with 
erlotinib 
2 38/Male/Asian 
Adenocarcinoma 
of the lung with 
bone metastases 
No D770_P772del_insKG in exon 20 Unknown 
Partial response, 
still progression 
free at 6 months 
(Figure 8) 
Received 
cetuximab with 
chemotherapy 
and 
bevacizumab 
3 65/male/Asian 
Adenocarcinoma 
of the lung 
with pleural, 
bones, and brain 
metastases 
No
Two mutations: 
Deletion in exon 
19 (15 base pair 
deletion (codons 
746–750) (nested 
around LREA string 
at 747 to 750)) 
T790M in exon 20 
Partial 
remission 
for 17 
months, 
then 
progression 
(at time 
that T790M 
detected) 
Rapid 
progression 
on cetuximab 
combined with 
erlotinib (given 
after progression 
on erlotinib, at 
time that T790M 
mutation was 
detected) 
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combination therapy would no longer be effective because 
of resistance of T790M to reversible TKI. 
Patients 
Three patients with known EGFR-(reversible 
TKI) resistant mutations (two with insertions in exon 20 
(Table 2, Cases 1 and 2) and one with an exon 20 T790M 
mutation (Case 3) were treated with an EGFR antibody 
(cetuximab)-based regimen. Both patients with insertions 
in exon 20 achieved durable partial remissions consistent 
with the predictions from our structural modeling (Table 
2, Figures 7 and 8). The third patient, having the exon 
19 (LREA-type) mutation, initially responded to the 
reversible TKI inhibitor erlotinib (partial remission for 
17 months); at the time that the T790M was detected, 
the patient failed to respond to erlotinib combined with 
cetuximab, again consistent with the molecular structure 
predictions. 
DISCUSSION
Our findings demonstrate that the exon 20 mutations 
EGFR D770_P772del_insKG and D770>GY (both 
resistant to EGFR reversible TKIs) [3] and exon 19 LREA 
del (EGFR reversible TKI-sensitive) [1], but not T790M 
(reversible TKI-resistant) [4, 5], can activate EFGR by 
increasing the attractive electrostatic energy between 
the monomer subunits of its kinase domains. The more 
attractive energies of interaction between the EGFR 
subunits would lead to more time that the receptor would 
stay in the active dimer conformation (Figure 1, Table 
1). A question that could be raised is whether the values 
of changes of electrostatic energy are significant enough 
to cause changes in stability of the dimer (Table 1). To 
address this question, we reviewed the energies of inter-
molecular interactions in known dimers of other proteins 
having dimensions that are close to those of the EGFR 
kinase domains. For the Ras–Raf dimer, the experimental 
value of inter-protein binding free energy is -40.2 kJ/mol 
Figure 6: Conformational changes due to LREA mutation. (A) WT EGFR interface between the kinase subunits in the region of 
exon 19. Negative GLU769 and positive ARG768 of the LREA loop region are located similar distances from the pair of negative aspartic 
acids ASP974 and ASP976, respectively, without significant impact to the electrostatic interaction between the subunits. (B) LREAdel 
mutant changes significantly the conformation of this loop and puts the positive ARG744 close to the above-mentioned pair of negative 
residues. This increases of the attractive energy of intersubunit interaction and leads to the more stable dimer state of the EGFR. 
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[19] and the theoretical value is -62.8+26.4 kJ/mol [20]. 
(For the Ras–RalGDS, the experimental and theoretical 
values are correspondingly -35.2 kJ/mol [19] and -81.6 
+24.7 kJ/mol [20].) For the “specially designed for 
electrostatic interaction” complex of barnase and barstar 
the calculated electrostatic energy is -61.9 kJ/mol [21]. 
Therefore, our values of electrostatic attractive energies 
from -60 to -93 kJ/mol (Table 1) are comparable with 
energies that are responsible for stability of other protein 
complexes. 
The results of our structural and electrostatic profile 
analysis suggest that an antibody such as cetuximab, which 
functions by preventing receptor dimerization, might be 
effective in exon 20 insertion aberrations and, to a lesser 
extent, in LREA exon 19 mutants. Cetuximab binds to 
EGFR domain III and covers an epitope that partially 
overlaps with the ligand-binding site. The heavy chain 
of cetuximab also sterically prevents domain I of EGFR 
from adopting the conformation required for dimerization 
[22–24]. 
Of interest in this regard, we report three patients 
treated with EGFR antibody cetuximab-based regimens 
(Table 2). Two of these patients had mutations considered 
resistant to EGFR TKI inhibitors (D770>GY and D770_
P772delsinKG (both in exon 20)), yet attained partial 
remissions on cetuximab-based therapy (Figures 7 and 
8). One patient continues to do well on treatment for 
over 3.5 years (Table 2, Patient #1, and Figure 7). In 
Figure 7: Computerized tomographic scan of the lungs of Patient #1 (Table 2) with EGFR aberration in exon 20 
(D770>GY)) before and four months after treatment with a cetuximab-based regimen shows tumor regression.
Figure 8: Computerized tomographic scan of the lungs of Patient #2 (Table 2) with EGFR exon 20 aberration D770_
P772del_insKG before and after treatment with a cetuximab-based regimen shows tumor regression. 
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contrast, a patient with the exon 20 T790M EGFR-TKI 
resistant mutation (in addition to the exon 19 sensitive 
LREAdel aberration) did not respond to the combination 
of cetuximab and erlotinib (Table 2, Patient #3). Typically, 
these patients present with the sensitive EGFR LREAdel 
aberrations and initially respond to reversible TKIs such as 
erlotinib (and, a salutary effect of erlotinib was indeed seen 
in our patient early in the disease course), but the resistant 
T790M mutation then emerges [4]. Similarly Janjigian 
and colleagues failed to show activity for the erlotinib/
cetuximab combination in patients with NSCLC and 
acquired resistance to erlotinib due to T790M mutations 
[25]. Our clinical observations are supported by the in 
silico modeling data (Figures 1 and 5), which demonstrate 
that exon 20 insertion aberrations would be expected to 
increase the attractive electrostatic dimerization energies, 
and such a change could be predicted to predispose to 
response to an EGFR antibody that attenuates or interferes 
with dimerization. Further, our modeling suggests that 
the LREA mutation can react to the combination of 
cetuximab and erlotinib, but the combination of LREA and 
T790M mutations can compromise this effect because of 
resistance of T790M mutant to TKI. Although there are 
limitations to this study, e.g., the small number of patients 
and the fact that the responders received combination 
therapy, the expected rate of response to the other drugs 
in the combination is low. These data suggest that some 
patients with gefitinib/erlotinib-resistant EGFR mutations, 
especially those in the amino acid 770 region of exon 20, 
may benefit from therapy with EGFR antibodies. 
Recently, several reports have postulated that the 
molecular heterogeneity and complexity of signaling 
in metastatic cancer can be distilled down to several 
pathways by analysis of convergence, interactions, and 
hubs [26–29]. While identifying convergence pathways 
is without a doubt important, it is also increasingly 
apparent that distinct mutations in the same gene or 
pathway can have vastly different effects, and real-time 
in silico modeling may therefore be an important tool 
for precision therapy. The current proof-of-principle 
report demonstrates cetuximab response in patients with 
EGFR aberrations in exon 20 (D770_P772del_insKG and 
D770>GY); these aberrations are resistant to EGFR TKIs. 
The response was predicted by in silico modeling, because 
the modeling showed that these molecular abnormalities 
activate EGFR by increasing the stability of the active 
dimer, and cetuximab is an EGFR antibody that interferes 
with dimerization. 
In conclusion, as analysis of oncogenic aberrations 
in patients with cancer is adopted in practice, there is 
often still an assumption that distinct abnormalities in 
the same gene produce a similar or identical effect. Yet 
the functional impact of distinct aberrations in the same 
gene may differ greatly. For instance, if a mutation 
increases interaction of the members of the dimer leading 
to activation of a kinase, the optimal treatment may be 
an antibody that interferes with dimerization. If, on the 
other hand, a mutation increases the activity of the kinase, 
facilitating a switch to an active conformation, the ideal 
treatment might be a compound that preserves the inactive 
conformation, etc. In silico modeling, such as that in the 
current proof-of-principle study, as well as computer-
based, decision-making systems, are therefore likely to 
be needed for best understanding anomalies in multiple 
genes beyond EGFR. It will be worthwhile to perform 
larger studies in order to confirm these observations and 
to determine if in silico modeling can be more widely 
exploited to precisely match patients harboring EGFR 
and other aberrations with drugs, so that response can be 
optimized.
MATERIALS AND METHODS
Rationale for molecular modeling use in these 
studies 
EGFR can form two different dimers. The first 
symmetric dimer is inactive, while the second, asymmetric 
dimer is active. EGFR dimerization activates the 
EGFR function. There are no direct residue-to-residue 
electrostatic contacts between the kinase domains of 
the active dimer, and electrostatic interactions are not 
considered as a main driving force of its formation. Indeed, 
the electrostatic interactions would not be the main reason 
for EGFR dimerization. Nevertheless in the active dimer 
there exists very close complementary contact between 
the kinase domains. Such a situation makes the dielectric 
constant in the interface zone comparable to the constant 
inside the protein. When such a condition arises, more 
distant than direct salt-bridge electrostatic interactions 
would became important. Mutations that increase 
electrostatic interactions between the kinase domains 
would keep the dimer in the active position longer and 
would increase the general activity of EGFR. To check 
this hypothesis, we measured the energy of electrostatic 
interaction between the kinase domains in the active 
EGFR dimer (for wt and mutated proteins). Structural 
modeling of EGFR kinase mutants has been used before 
for prediction of EGFR drug resistance to erlotinib and 
gefitinib [14] and cetuximab [30] based on calculations 
of energies of drug-protein interactions. Nevertheless, to 
our knowledge, there are no reports describing modeling 
of EGFR mutants’ impact on this protein’s dimerization 
and consequent activation, and the clinical implications in 
individual patients.
The mutations studied (D770_P772del_insKG, 
D770>GY, and del747–750 (LREA)) include charged 
residues. These mutations are not just substitutions 
of one amino acid to another. D770_P772del_insKG 
makes the region shorter by one amino acid; D770>GY, 
Oncotarget6037www.impactjournals.com/oncotarget
longer by one amino acid; LREA, shorter by four amino 
acids. In all these cases, such changes would affect the 
tertiary structure of the protein. To elucidate a molecular 
mechanism explaining the function of these mutations, 
we conducted modeling of EGFR tertiary structure, and 
measured the effect of the mutations on interactions 
between two kinase domains of the EGFR dimer in the 
active state.
Theoretical methods 
We used the crystal structure of the active dimer of 
the kinase domains of EGFR—PDB ID 2GS6 [31]. For 
defining afatinib’s position in T790M EGFR, we used 
the structures with PDB IDs 4G5P and 4G5J [17]. For 
modeling of all mutants, we used the Homology program 
from the InsightII program package (Accelrys, San Diego, 
CA). For measurement of electrostatic energy between 
the EGFR subunits, we used the non-linear Poisson–
Boltzmann method as presented in the DELPHI program 
using AMBER forcefield [32, 33]. The dielectric constants 
4 for protein and 78.6 for water were used. The potential 
profiles were calculated with Swiss-PdbViewer4.0.1 
(www.expasy.org/spdbv/). 
Patients 
Structural modeling of EGFR mutants was used, 
along with results of Clinical Laboratory Improvement 
Amendments (CLIA)-approved molecular tests for 
EGFR (next generation sequencing or polymerase 
chain reaction (PCR)-based sequencing). The index 
patient (Table 2, Case 2) was assessed to predict EGFR 
antibody responsiveness; this patient had an insertion 
exon 20 mutation known to be resistant to EGFR small 
molecule reversible kinase inhibitors [3]. (Modeling 
suggested increased responsiveness to an EGFR antibody 
for the insertion exon 20 mutations, but not for T790M 
exon 20 mutation.) The patient was treated with an 
EGFR antibody-containing regimen and outcomes, 
including tumor regression, ascertained using RECIST 
measurements [34]. The results of a twenty patient trial 
using a cetuximab-based regimen for lung cancer was 
then retrospectively analyzed for patients with resistant 
EGFR mutations [35]. The outcomes of the two patients 
harboring such mutations (Table 2, Cases 1 and 3) were 
evaluated. The study was performed consistent with the 
Internal Review Board guidelines for the University 
of California San Diego and University of Texas MD 
Anderson Cancer Center (depending on where they were 
treated). 
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